FDA approves Tandem’s connected insulin controllerTandem Diabetes Care has claimed approval in the US for a new software system that can be used Share XFDA approves Tandem’s connected insulin controllerhttps://pharmaphorum.com/news/fda-approves-tandems-connected-insulin-controller/
Sanofi builds case for Toujeo in younger type 1 diabeticsSanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but Share XSanofi builds case for Toujeo in younger type 1 diabeticshttps://pharmaphorum.com/news/sanofi-builds-case-for-toujeo-in-younger-type-1-diabetics/
Astellas cuts $795m deal with Pandion for type 1 diabetes drugsAstellas Pharma is boosting its early-stage pipeline with a $45 million upfront deal to license bispecific antibodies from Share XAstellas cuts $795m deal with Pandion for type 1 diabetes drugshttps://pharmaphorum.com/news/astellas-biotech-deal-pandion-diabetes/
Giving patients a sense of belongingClinical research professional and patient advocate Kristina Wolfe tells us how pharma can collaborate better with patients and Share XGiving patients a sense of belonginghttps://pharmaphorum.com/views-analysis-patients/giving-patients-a-sense-of-belonging/
Vertex looks beyond cystic fibrosis with $950m Semma buyVertex Pharma is all-but synonymous with cystic fibrosis (CF) treatment but wants to diversify into new areas, including Share XVertex looks beyond cystic fibrosis with $950m Semma buyhttps://pharmaphorum.com/news/vertex-looks-beyond-cystic-fibrosis-with-950m-semma-buy/
Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerGlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid Share XRelief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerhttps://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/
FDA unconvinced by Sanofi’s Zynquista in type 1 diabetesSanofi’s hopes of getting its dual SGLT inhibitor sotagliflozin approved alongside insulin for type 1 diabetes in the Share XFDA unconvinced by Sanofi’s Zynquista in type 1 diabeteshttps://pharmaphorum.com/news/fda-unconvinced-by-sanofis-zynquista-in-type-1-diabetes/
FDA advisers divided on Sanofi’s oral type 1 diabetes drugThe future of Sanofi and Lexicon’s oral diabetes drug Zynquista hangs in the balance after an FDA advisory Share XFDA advisers divided on Sanofi’s oral type 1 diabetes drughttps://pharmaphorum.com/news/fda-divided-on-sanofis-oral-type-1-diabetes-drug/
Novo to create California stem cell therapy manufacturing siteNovo Nordisk has announced the establishment of a manufacturing site in Fremont, California, US to develop and produce Share XNovo to create California stem cell therapy manufacturing sitehttps://pharmaphorum.com/news/novo-to-create-california-stem-cell-therapy-manufacturing-site/
